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Department of Pathology and Immunologya and Department of Medicine, Division of Bone and Mineral Diseases,b Washington University School of Medicine, St. Louis,
Missouri, USA; Department of Biochemistry, University of Leicester, Leicester, United Kingdomc; Department of Medicine, University of California, San Diego, La Jolla,
California, USAd; Unit on Behavioral Genetics, Laboratory of Molecular Pathophysiology, National Institute of Mental Health, National Institutes of Health, Bethesda,
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To determine talin1’s role in osteoclasts, we mated TLN1fl/fl mice with those expressing cathepsin K-Cre (CtsK-TLN1) to delete
the gene in mature osteoclasts or with lysozyme M-Cre (LysM-TLN1) mice to delete TLN1 in all osteoclast lineage cells. Absence
of TLN1 impairs macrophage colony-stimulating factor (M-CSF)-stimulated inside-out integrin activation and cytoskeleton or-
ganization in mature osteoclasts. Talin1-deficient precursors normally express osteoclast differentiation markers when exposed
to M-CSF and receptor activator of nuclear factor B (RANK) ligand but attach to substrate and migrate poorly, arresting their
development into mature resorptive cells. In keeping with inhibited resorption, CtsK-TLN1 mice exhibit an5-fold increase in
bone mass. Osteoclast-specific deletion of Rap1 (CtsK-Rap1), which promotes talin/ integrin recognition, yields similar osteo-
petrotic mice. The fact that the osteopetrosis of CtsK-TLN1 and CtsK-Rap1 mice is substantially more severe than that of those
lackingv3 is likely due to added failed activation of 1 integrins. In keeping with osteoclast dysfunction, mice in whom talin
is deleted late in the course of osteoclastogenesis are substantially protected from ovariectomy-induced osteoporosis and the
periarticular osteolysis attending inflammatory arthritis. Thus, talin1 and Rap1 are critical for resorptive function, and their
selective inhibition in mature osteoclasts retards pathological bone loss.
The osteoclast is the principal, if not exclusive, skeletal resorp-tive cell whose activity is initiated by contact with bone. In all
cells, including osteoclasts, integrins recognize substrate, partici-
pate in cytoskeletal organization, and transmit matrix-derived sig-
nals, events essential to the resorptive process (1, 2).
v3 is the principal integrin mediating the osteoclast’s capac-
ity to resorb bone. This heterodimer remodels the cell’s cytoskel-
eton via recruitment of a complex including c-Src, Syk, Dap12,
SLP-76, and Vav3. In consequence, the cytoskeleton-organizing
GTPase Rac transits from its inactive GDP- to its active GTP-
bound form. Absence of any component of this signaling pathway
yields a common osteoclast phenotype with a deranged cytoskel-
eton and inability to spread (3–8). Macrophage colony-stimulat-
ing factor (M-CSF), which promotes osteoclastogenesis, also or-
ganizes the cytoskeleton of the mature bone resorptive cell by
activating a signaling complex strikingly similar to that stimulated
by v3 (9, 10).
In osteoclasts, v3 mediates bone matrix recognition by
binding ligands containing the RGD motif, but its ability to do so
depends upon its configuration. Like integrins in other cells,v3
in the osteoclast is maintained in a default low-affinity state by
interactions between the  and  subunits (11, 12). In its inactive
conformation, the integrin heterodimer assumes a “bent” config-
uration in which the  and  intracellular domains interact via a
membrane-proximal salt bridge. Upon integrin activation (i.e.,
increased affinity), the salt bridge is disrupted, the cytoplasmic
tails separate, and the extracellular domain “straightens” to achieve a
configuration permitting it to effectively bind ligand (13).
Integrins are activated by two basic mechanisms (13). Out-
side-in activation is achieved by initial ligand binding, which
causes secondary conformational modifications, further enhanc-
ing the integrin’s affinity. Outside-in conformational change can
also be induced by chemicals or monoclonal antibodies (MAbs)
prior to ligand binding. Inside-out activation, on the other hand,
is an indirect process in which signals derived from an occupied
receptor, typically that of a cytokine or growth factor, target the
intracellular domain of an integrin. Such targeting of v3 dis-
rupts its salt bridge, separates its tails, and straightens the bent
conformation of its external domain. The integrin is now posi-
tioned to bind ligand with high affinity and transmit matrix-de-
rived signals, including those that organize the cytoskeleton.
Virtually all studies of integrin function in the osteoclast have
focused on outside-in signaling. These experiments typically en-
tail parachuting suspended, preterminally differentiated osteo
clastic cells onto an v3 ligand. This approach, however, does
not mirror the resorptive process, in which osteoclasts are at-
tached to the bone surface and constantly remodel their cytoskel-
eton as they move and degrade skeletal tissue. Nor does it mimic
the physiological setting, in which cells are exposed to an array of
cytokines and growth factors with the potential to alter integrin
conformation.
Talin is a 270-kDa cytosolic adaptor protein that links  integ-
rins to the actin cytoskeleton and in so doing regulates multiple
biological events such as macrophage participation in innate im-
munity (14). In all cells studied, the interaction between talin and
the -integrin cytoplasmic domain is a final common and neces-
sary step to inside-out integrin activation (15). The high-affinity
heterodimer now avidly binds extracellular ligand, which stimu-
lates the transmission of intracellular signals, including those that
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organize the cytoskeleton. We find that M-CSF, which activates
v3 in osteoclasts, promotes the association of integrin with
talin via Y747 in the 3 tail. Likely reflecting the inhibition of
multiple integrins, we also note that conditional deletion of talin
or its activator Rap1, in mature osteoclasts, arrests the resorptive
function and increases bone mass substantially more than does
absence of v3. Additionally, osteoclast-specific talin deletion
protects against estrogen-deficient osteoporosis and inflamma-
tory osteolysis. Our observation that the pronounced bone-spar-
ing effect of deleting talin or Rap1 occurs only in committed bone
resorbing cells gives credence to a therapeutic strategy that avoids
targeting early osteoclast precursors such as macrophages. Hence,
the Rap1/talin signaling complex is a necessary component of
physiological and pathological bone resorption.
MATERIALS AND METHODS
Mice. Generation of Tln1fl/fl, 3Y747A, and Rap1Afl/fl Rap1Bfl/fl mice has
been described (16–18). CtsKcre/ mice were provided by S. Kato (Uni-
versity of Tokyo, Tokyo, Japan) (19). LysMCre-expressing mice were pur-
chased from the Jackson laboratory. To obtain mice with talin1-deficient
macrophages (LysM-TLN), Tln1fl/fl LysMCre/WT males were bred with
Tln1fl/flLysMCre/WT females. In all experiments,Tln1fl/flCreorRap1A/
Bfl/fl Cre mice were compared with Tln1fl/fl Cre or Rap1A/Bfl/fl Cre
sex-matched littermates.
Reagents. Recombinant murine M-CSF was obtained from R&D Sys-
tems (Minneapolis, MN). Glutathione S-transferase-receptor activator of
nuclear factor B ligand (GST-RANKL) was expressed in our laboratory
as described previously (6). The sources of antibodies are as follows:
mouse antitalin MAbs and antiactin antibodies were from Sigma (St.
Louis, MO); antiphosphotyrosine MAb 4G10 was from Upstate (Charlot-
tesville, VA); MAb 327, directed against the c-Src protein, was a gift of A.
Shaw (Department of Pathology, Washington University School of Med-
icine, St. Louis, MO); rabbit anti-Src p-Y416 antibody and rabbit anti-3
integrin antibody were from Cell Signaling (Beverly, MA). Anti-NFATc1,
anti-Rap1A, and anti-Rap1B antibody were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). WOW1 ligand mimetic, which recog-
nizes activatedv3 integrin, was provided by Sanford Shattil (University
of California at San Diego). All other chemicals were obtained from
Sigma.
Macrophage isolation and osteoclast culture. Primary bone marrow
macrophages (BMMs) were prepared as described previously (6), with
slight modification. Marrow was extracted from femora and tibiae of 6- to
8-week-old mice with -minimal essential medium (-MEM) and cul-
tured in -MEM containing 10% inactivated fetal bovine serum (FBS),
100 IU/ml penicillin, and 100 g/ml streptomycin (-10 medium) with
1:10 CMG medium (conditioned medium containing 100 ng/ml mouse
M-CSF) (20) on bacterial plastic dishes. Cells were incubated at 37°C in
6% CO2 for 3 days and then washed with phosphate-buffered saline (PBS)
and lifted with 1 trypsin/EDTA (Invitrogen, Carlsbad, CA) in PBS. A
total of 5  103 cells were cultured in 200 l -MEM containing 10%
heat-inactivated FBS with 100 ng/ml GST-RANKL and 30 ng/ml of mouse
recombinant M-CSF in 96-well tissue culture plates, some containing
sterile bone slices. Cells were fixed and stained for tartrate-resistant acid
phosphatase (TRAP) activity after 6 days in culture, using a commercial
kit (Sigma 387-A, St. Louis, MO). For preosteoclast generation, 1.5 106
BMMs were plated per 10-cm tissue culture dish and maintained in 30
ng/ml M-CSF and 100 ng/ml GST-RANKL for 3 days.
Actin ring and bone resorptive pit visualization. For actin ring stain-
ing, cells were cultured on bovine bone slices in the presence of M-CSF
and RANKL for 6 days, after which cells were fixed in 4% paraformalde-
hyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and immuno-
stained with AlexaFluor 488-phalloidin (Molecule Probes). To quantitate
resorption lacunae, cells were removed from bone slices with mechanical
agitation. Bone slices were incubated with peroxidase-conjugated wheat
germ agglutinin (WGA) (Sigma) for 1 h and stained with 3,3=-diamino-
benzidine (Sigma).
Plasmids and retroviral transduction. Talin head constructs contain-
ing amino acids 1 to 433 were inserted into a pMX retrovirus vector in
which the puromycin resistance sequence was replaced with one coding
for blasticidin resistance. Generation of the pMX Turbo-Cre construct
has been described (21). It was transfected transiently into Plat-E packag-
ing cells using FuGENE 6 transfection reagent (Roche). Virus was col-
lected 48 h after transfection. BMMs were infected with virus for 24 h in
the presence of 100 ng/ml M-CSF and 4 g/ml Polybrene (Sigma). Cells
were selected in the presence of M-CSF and 1 g/ml blasticidin (Calbio-
chem) for 3 days prior to use as osteoclast precursors.
RNA preparation and RT-PCR analyses. Total RNA from cultured
cells was isolated using the Total RNA Isolation kit (Sigma). For reverse
transcription-PCR (RT-PCR) analysis, cDNAs were synthesized from 1
g of total RNA using reverse transcriptase and oligo(dT) primers in a
volume of 20 l. The reaction mixture was adjusted to 100 l with Tris-
EDTA (TE) buffer for PCR analysis. PCR was performed with 1 l of
cDNA reaction mixture by using Platinum Pfx polymerase (Invitrogen,
Carlsbad, CA) and appropriate primers in a volume of 50 l. The follow-
ing primers were used: for Tln1, 5=-CAGAGGCCGTAGAAGACCTG and
3=-GGCTGGTGTTTGACTTGGTT; for Tln2, 5=-TGCAATGTGGTGAA
GACCAT and 3=-GTGTCCGACCTGCTTCTAGC; and for b3, 5=-TTAC
CCCGTGGACATCTACTA and 3=-AGTCTTCCATCCAGGGCAATA.
Western blotting and immunoprecipitation. Cultured cells were
washed twice with ice-cold PBS and lysed in radioimmunoprecipitation
assay (RIPA) buffer containing 20 mM Tris [pH 7.5], 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophos-
phate, 1 mM -glycerophosphate, 1 mM Na3VO4, 1 mM NaF, and 1
protease inhibitor mixture (Roche). After incubation on ice for 10 min,
cell lysates were clarified by centrifugation at 21.1  103 g for 10 min.
Forty micrograms of total lysates was subjected to 8% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred onto poly-
vinylidene difluoride (PVDF) membranes. Filters were blocked in 0.1%
casein in PBS for 1 h and incubated with primary antibodies at 4°C over-
night followed by probing with fluorescence-labeled secondary antibodies
(Jackson Lab). Proteins were detected with the Odyssey Infrared Imaging
system (LI-COR Biosciences).
Rac1 and Rap1 activation assay. Preosteoclasts cultured on plastic
dish or bone powder were stimulated with M-CSF and lysed, and Rac or
Rap1 activity was determined by an effector domain, GST-fusion pull-
down protocol using the EZ-detect Rac1 or Rap1activation kit (Pierce
Biotechnology Inc.).
Medium CTx-1 assay. Macrophages were cultured on bone with 100
ng/ml RANKL and 1/100 volume CMG14-12 mouse M-CSF-producing
cell line (20) supernatant for 6 days. The medium (-10) was changed 1
day before harvesting. Medium CTx-1 concentration was determined us-
ing the CrossLaps for Culture enzyme-linked immunosorbent assay
(ELISA) kit (Nordic Bioscience Diagnosis A/S).
Phagocytosis assay. Thymocytes isolated from 4-week-old C57BL/6
mice were 	-irradiated (1,400 rads) and cultured for 4 h to induce apop-
tosis. Thymocytes were 50 to 60% apoptotic as assessed by fluorescein
isothiocyanate (FITC)-annexin V (BD Pharmingen) and 7-ADD (Calbio-
chem) staining (annexin V, 7-ADD). CFSE (5,6-carboxyfluorescein
diacetate succinimidyl ester) (5 M) was used to label thymocytes for 10
min at room temperature. Labeled thymocytes were cocultured with mac-
rophages at a ratio of 5:1 at 37°C. Cells were harvested with PBS-EDTA,
stained with CD11b-allophycocyanin (CD11b-APC), and analyzed by
flow cytometry. The percentage of phagocytosis was calculated as the frac-
tion of CD11b cells that were positive in the FL1 channel.
Serum osteocalcin measurements. Blood was collected retro-orbit-
ally under anesthesia immediately prior to sacrifice. Serum osteocalcin
levels were measured by ELISA (Biomedical Technologies Inc.). Plasma
was obtained using plasma separator tubes with lithium heparin (Becton,
Dickinson).
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Microcomputed tomography (CT). The trabecular volume in the
distal femoral metaphysis or proximal tibia was measured using a Scanco
CT40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). A thresh-
old of 250 was used for evaluation of all scans. Forty to 100 slices were
analyzed, starting with the first slice in which condyles and primary spon-
giosa were no longer visible.
Calcein labeling. We injected calcein (Sigma) intraperitoneally at 7.5
mg/kg of body weight on days 7 and 2 before killing and then sectioned
tibiae in methyl-methacrylate, which were analyzed using BioQuant
OsteoII (BioQuant Image Analysis Corporation, Nashville, TN).
Serum transfer arthritis and histological analysis. Arthrogenic se-
rum was obtained from K/BN mice (6 to 12 weeks old). Serum (100l
per mouse) was injected intraperitoneally on days 7 and 2 prior to sacri-
fice, whereas 100 l of PBS was administered to control animals. Five or
more mice were used for each group. Paw thickness was measured daily.
Histology and histomorphometry. The tibiae of 2-month-old mice
were fixed with 10% neutral buffered formalin, followed by decalcifica-
tion in 14% EDTA for 10 days, paraffin embedding, and TRAP staining.
Osteoclastic perimeters were measured and analyzed using BioQuant Os-
teoII (BioQuant Image Analysis Corporation, Nashville, TN) in a blinded
fashion. Pit areas were measured with ImageJ.
Statistics. Statistical significance was determined using Student’s t
test. All experiments were performed at least twice.
RESULTS
M-CSF stimulates inside-out activation of the v3 integrin in
osteoclasts. The fact that the signaling events by which M-CSF
alters the osteoclast cytoskeleton are similar to those mediated by
activated v3 suggests a collaborative association. Confirming
cytokine dependence on the integrin, M-CSF activation of Rac,
the currently established most distal component of a canonical
osteoclast cytoskeleton organizing complex, requires v3 (Fig.
1A). Establishing that the collaboration betweenv3 and M-CSF
reflects inside-out stimulation, the cytokine approximately dou-
bles binding of WOW1, an v3 ligand mimetic recognizing the
activated integrin (Fig. 1B). Furthermore, v3 progressively as-
sociates with talin under the influence of M-CSF (Fig. 1C), which
also promotes talin migration from the podosome belt to cyto-
kine-induced fillipodia (Fig. 1D).
3Y747 regulates talin-mediated cytoskeletal organization in
osteoclasts. In other cells, optimal integrin activation requires
talin recognition of 3Y747 (17). To determine if the same is true
regarding the organization of the osteoclast cytoskeleton, bone
marrow macrophages (BMMs) of knock-in mice bearing an ala-
nine mutation of the residue were differentiated into osteoclasts in
vitro. These cells, while normal in number, develop the same non-
spread, crenated appearance extant in osteoclasts lacking the 3
integrin or its cytoskeleton-organizing effectors (Fig. 2A and B)
(3–8). The abnormal appearance of these mutant cells does not
represent arrested differentiation (Fig. 2C). Like cultured 3-de-
ficient osteoclasts, 3Y747A cells generate actin rings, but their
bone-resorptive activity is diminished (Fig. 2D to G).
Immunoblots of 3 immunoprecipitates document that M-
CSF promotes talin association with wild-type (WT) 3, but not
3Y747A (Fig. 2H). In contrast to 3Y747A osteoclasts, those ex-
pressing nonphosphorylatable3Y747F are essentially normal (22).
Like WT, 3Y747F completely rescues 3/ osteoclasts, whereas
3Y747A is unable to do so (Fig. 2I). Thus, the mechanism by which
3Y747A disrupts the cytoskeleton does not reflect arrested phos-
phorylation. Unlike what is seen in3/mice, no change in bone
mass is evident in those bearing the 3Y747A mutation at 6 months
of age (Fig. 2J) (23), but they are protected from postmenopausal
FIG 1 M-CSF activates v3 in osteoclasts. (A) Cytokine-starved, bone-re-
siding WT and 3/ prefusion osteoclasts were M-CSF treated over time.
Total and GTP-bound Rac levels were determined. (B) Prefusion osteoclasts
were cytokine starved, lifted, and treated with M-CSF or carrier for 30 min.
WOW1 binding was analyzed by fluorescence-activated cell sorting (FACS).
Control binding is normalized to 100% (*, P 
 0.05). (C) Cytokine-starved
3/ prefusion osteoclasts transduced with WT human 3 were treated with
M-CSF over time. 3 immunoprecipitates were immunoblotted for talin, and
the blot was densitometrically analyzed. (D) Cytokine-starved osteoclasts gen-
erated from WT BMMs were exposed to M-CSF or carrier for 30 min. The cells
were stained for F-actin (green) and talin (red). Arrows indicate fillipodia
induced by the cytokine. Bar, 50m. Data are representative of 3 independent
experiments for panels A to C and 2 experiments for panel D. Numbers next to
the gels represent molecular weights (in thousands).
Zou et al.
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FIG 2 3Y747 regulates osteoclast function. (A) WT or 3Y747A (YA) BMMs were cultured in M-CSF and RANKL for 5 days and stained for TRAP activity. Bar,
200 m. (B) Quantification of the osteoclasts (Ocs) shown in panel A. (C) WT and 3Y747A BMMs were cultured in M-CSF and RANKL. The osteoclast
differentiation markers, 3 integrin subunit, NFATc1, and c-Src, were immunoblotted with time. Actin served as loading control. (D) WT and 3Y747A BMMs
were cultured in M-CSF and RANKL on bone slices for 6 days. Rhodamine-phalloidin-stained actin rings were visualized by fluorescence microscopy. Bar, 100
m. (E) After 6 days, the cells were removed and resorption pits visualized by peroxidase-labeled wheat germ agglutinin staining. Bar, 100m. (F) Quantitation
of resorption pits visualized in panel E. (G) Medium collected from cultures shown in panel E was analyzed for CTx content. (H) Cytokine-starved 3/
prefusion osteoclasts transduced with WT or Y747A human3 were treated with M-CSF or carrier for 30 min.3 immunoprecipitates were probed for talin. 3
integrin served as loading control. (I) Osteoclasts generated from 3/ BMMs transduced with WT, Y747A, or Y747F (YF) human 3 or empty vector were
stained for TRAP activity (upper panels; bar, 400 m). Expression of 3 constructs (lower panel) with actin as loading control. (J) CT image of distal femoral
metaphysis of 6-month-old WT and 3Y474A knock-in mice. (K) CT images of distal femur of WT and 3Y747A mice 4 weeks after ovariectomy. (L) CT
determination of BV/TV of WT and 3Y747A mice 4 weeks after ovariectomy. n 3 per group (*, P
 0.05; **, P
 0.01). Data are representative of at least 3
independent experiments (panels A through F and J through L) or 2 experiments (panels G and H). Numbers next to the gels represent molecular weights (in
thousands).
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FIG 3 TLN1 deletion in mature osteoclasts causes osteopetrosis. (A) TLN1 and TLN2 mRNA expression in WT BMMs (M) and osteoclasts (OC) assessed by
RT-PCR. The 3 integrin subunit serves as a marker of osteoclast differentiation and actin as loading control (left panel). To validate TLN2 primers, mRNA
expression by macrophages (M), osteoclasts, and osteoblasts (OB) was determined by quantitative PCR (right panel). (B) Radiographs of femurs and
tibias/fibulas of 8-week-old control () and CtsK-TLN1 () mice. (C) CT images of distal femoral metaphysis (middle and lower panel) and proximal tibia
(upper panels) of control () and CtsK-TLN1 () mice. (D) CT determination of BV/TV, trabecular connectivity, and volumetric bone mineral density
(BMD) of distal femoral metaphysis of control () and CtsK-TLN1 () mice. (E) Whole-body dual-energy X-ray absorptiometry (DEXA) analysis of areal BMD
of control () and CtsK-TLN1 () mice. (F) TRAP-stained histological sections of proximal tibia of 8-week-old control () and CtsK-TLN1 () mice. Bars: 500
m (upper panel), 50m (lower panel). (G) The total number of osteoclasts normalized to bone surface and the percentage of bone surface to which osteoclasts
are juxtaposed in panel F were histomorphometrically determined (*, P
 0.05; ***, P
 0.001). Data are representative of 2 independent experiments in panel
A. At least 10 animals were included in each group in panels B to F and 5 animals in panel G.
Zou et al.
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bone loss (Fig. 2K and L) (24). Hence, 3Y747 is essential for talin
recognition by the integrin in osteoclasts.
Talin1-deficient osteoclasts are dysfunctional in vivo. In
some cell types, talin2 can compensate for loss of talin1, but only
talin1 is expressed by osteoclasts and their precursors (Fig. 3A)
(25, 26). Therefore, we crossed mice with a conditional TLN1
allele to those expressing cathepsin K Cre (CtsK-Cre), which is
active only in mature osteoclasts (19) (mice and osteoclasts with
conditional deletion of TLN1 by CtsK-Cre are here referred to as
CtsK-TLN1). In keeping with diminished resorptive activity,
CtsK-TLN1 tibias and femurs are more radiodense than control
tibias and femurs (Fig. 3B). Similarly, trabecular bone mass and
connectivity, determined by CT, is substantially increased in
CtsK-TLN1mice, as are volumetric and whole-body bone mineral
density (BMD) (Fig. 3C to E). Histological analysis confirms en-
hanced trabecular bone volume (BV/TV) in the mutant mice, de-
spite normal numbers of osteoclasts (Fig. 3F and G). In contrast,
histomorphometrically measured bone formation rates in Cre
and Cre mice are indistinguishable, as is the circulating osteo-
blast function marker osteocalcin (Fig. 4A to D). In keeping with
the skeletal consequences of talin deletion likely representing tar-
geting of integrins in addition tov3, CtsK-mediated deletion of
only the latter does not impact bone mass in 8-week-old mice (Fig.
4E and F).
Rap1-deficient osteoclasts are dysfunctional. Despite the rel-
atively robust in vivo phenotype of CtsK-TLN1 mice, osteoclasts
generated in vitro, for 5 days, are normal (Fig. 5A). As seen in Fig.
5B, this unexpected phenomenon likely represents undiminished
talin1 protein in these cells until 6 days of culture, the limit of their
in vitro viability. To circumvent this limitation, we attempted, but
failed, to delete the gene by transducing TLN1fl/fl-bearing BMMs
with Cre recombinase-transduced retrovirus (not shown). Based
upon our previous experience that the success of in vitro Cre-
mediated deletion is gene specific (21, 27), we turned to Rap1, a
Ras family GTPase, which in conjunction with Rap1 interacting
adaptor molecule (RIAM) mediates talin/integrin recognition
(28). Like its effect on Rac (Fig. 1A), M-CSF transits Rap1 to its
active, GTP-bound form in prefusion osteoclasts (Fig. 5C).
FIG 4 TLN1 deletion in mature osteoclasts does not affect bone formation. (A to D) CtsK-TLN1 () and control () mice were administered two time-spaced
doses of calcein. (A) Fluorescence microscopic images of proximal tibia. Bars: 400m (upper panel), 100m (lower panel). Calculation of bone formation rates
(BFR) (B) and mineral apposition rates (MAR) (C). (D) Circulating osteocalcin of CtsK-TLN1 () and control () mice. (E and F) 3fl/fl mice (generated by
Katherine Weilbaecher, Washington University School of Medicine) were crossed to those expressing Ctsk-Cre. (E)3 subunit and c-Src immunoblots of lysates
of Cre and Cre BMMs exposed to M-CSF (M), or M-CSF RANKL (OC) for 6 days. Actin served as loading control. (F) CT images of 8-week-old Cre
and Cre progeny. n 5 in each group in panels A to D; n 3 in panel F. Data are representative of at least 2 independent experiments. Numbers next to the
gel represent molecular weights (in thousands).
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In contrast to our attempts to target TLN1fl/fl, Cre-mediated
deletion of Rap1Afl/fl/Rap1Bfl/fl in vitro was successful (Fig. 5D).
This exercise produced osteoclasts exhibiting the characteristic
crenated appearance of those lacking integrin-activated, cytoskel-
eton-organizing molecules and with compromised bone-resorp-
tive capacity (Fig. 5E to G). In keeping with failed integrin activa-
tion, Cre Rap1 BMMs normally express differentiation markers
under osteoclastogenic conditions (Fig. 4H). Furthermore, li-
ganding of v3 does not phosphorylate its effector, Vav3 (Fig.
4I), and M-CSF fails to prompt talin/3 association in the gene-
deleted, prefusion osteoclasts (Fig. 4J).
Mice with Rap1-deficient osteoclasts are osteopetrotic. To
determine the physiological relevance of Rap1 in osteoclasts, we
crossed Rap1Afl/fl/Rap1Bfl/fl mice to those expressing CtsK-Cre,
generating animals whose in vivo phenotype mirrors those with
conditional deletions of talin in that they develop a marked in-
crease in bone mass despite an abundance of osteoclasts (Fig. 6A
to E) (mice and osteoclastic cells with conditional deletions of
Rap1A/B by CtsK-Cre are here referred to as CtsK-Rap1). CtsK-in-
duced loss of Rap1A/B is apparent within 3 days of exposing CtsK-
Rap1 BMMs to M-CSF and receptor activator of nuclear factor B
ligand (RANKL) (Fig. 6F). In keeping with this early deletion, CtsK-
Rap1 osteoclasts so generated have the crenated appearance charac-
teristic of cytoskeletal disarray (Fig. 6G). Thus, disruption of Rap1/
talin activity arrests integrin function in osteoclasts and inhibits their
resorptive activity in vitro as well as in vivo.
Talin1-deficient osteoclast lineage cells are dysfunctional.
Our previous experiments indicate that talin deletion late in
osteoclastogenesis produces osteopetrosis in vivo but fails to yield
an abnormal phenotype ex vivo. Given the success of in vitro Rap1
targeting, however, we reasoned that deleting TLN1 in early
osteoclast lineage cells in vivo would obviate this limitation. To
this end, we matedTLN1fl/fl mice with those expressing Cre driven
by the lysozyme M (LysM) promoter, expressed in all myeloid
lineage cells (osteoclast lineage cells with conditional deletion of
TLN1 by LysM-Cre are here referred to as LysM-TLN1). Talin1 is
reduced by approximately 65% in LysM-TLN1 cells (Fig. 7A),
while expression of kindlin 3 mRNA, whose product binds and
activates integrins, is intact (29–31).
Similar to what is seen in CtsK-TLN1 mice, the number of
osteoclasts in LysM-TLN1 animals is indistinguishable from that
of the control (not shown). While the change is not as dramatic as
that occurring in the context of CtsK-Cre, trabecular bone volume
of LysM-TLN1 mice is also significantly increased (Fig. 7B).
Whereas cultured CtsK-TLN1 osteoclast lineage cells appear nor-
mal, LysM-TLN1 precursors cluster and largely fail to attach to
and spread on substrate, features consistent with integrin dys-
FIG 5 Rap1-deficient osteoclasts are dysfunctional in vitro. (A) CtsK-TLN1 () and control () BMMs maintained in M-CSF and RANKL for 5 days were
stained for TRAP activity. Bar, 400 m. (B) CtsK-TLN1 BMMs were exposed to M-CSF and RANKL for 2 to 6 days or M-CSF (M) for 6 days. Talin1 and Cre
expression were determined by immunoblotting. The 3 integrin subunit serves as a marker of osteoclast differentiation and actin as loading control. (C)
Cytokine-starved, WT prefusion osteoclasts were exposed to increasing amounts of M-CSF for 15 min. Lysate containing GTP-Rap1 was measured by pulldown
assay. Total Rap1 served as loading control. (D) Rap1Afl/fl  Rap1Bfl/fl BMMs were transduced with Cre recombinase () or vector (). Lysates were
immunoblotted for Rap1A and Rap1B. Actin served as loading control. (E) Rap1Afl/fl Rap1Bfl/fl Cre and Cre BMMs were exposed to RANKL and M-CSF
for 5 days and stained for TRAP activity. Bar, 100m. (F) The cells were removed and resorption pits (dark brown reaction product) visualized by staining with
wheat germ agglutinin. Bar, 100m. (G) Medium was analyzed for CTx content. (H) Rap1Afl/flRap1Bfl/fl Cre and Cre BMMs were treated with M-CSF and
RANKL for 2 to 5 days or M-CSF (M) alone for 5 days. NFATc1,3 integrin, and c-Src were immunoblotted. Actin served as loading control. (I) Cytokine-starved
Rap1Afl/fl  Rap1Bfl/fl Cre and Cre prefusion osteoclasts were lifted and maintained in suspension (S) or plated on vitronectin (A) for 30 min. Vav3
immunoprecipitates were immunoblotted for phosphotyrosine (p-Y) and Vav3. (J) Cytokine-starvedRap1Afl/flRap1Bfl/fl Cre and Cre prefusion osteoclasts
were exposed to M-CSF or carrier for 30 min. 3 integrin immunoprecipitates were immunoblotted for talin and 3 subunit. Data are representative of at least
3 independent experiments in panels A to F and H to J and 2 in panel G. Numbers next to the gels represent molecular weights (in thousands).
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FIG 6 Rap1 deletion in mature osteoclasts causes osteopetrosis. (A) X-rays of femurs of CtsK-Rap1 () and control () mice demonstrating enhanced
radiodensity of the former. (B)CT images of femurs of CtsK-Rap1 and control mice. (C) QuantitativeCT data of femurs of CtsK-Rap1 and control mice. (D)
TRAP-stained (red reaction product) histological sections of tibias of CtsK-Rap1 and control mice. Bars: 500 m (upper panel), 100 m (lower panel). (E)
Histomorphometric quantification of trabecular bone volume and osteoclast abundance shown in panel D. (F) CtsK-Rap1 BMMs were exposed to M-CSF and
RANKL for 2 to 6 days or M-CSF (M) for 6 days. Rap1b expression was determined by immunoblotting. Actin served as loading control and c-Src as a marker
of differentiation. (G) Control () and CtSk-Rap1 () BMMs were cultured with M-CSF and RANKL for 4 days, after which they were stained for TRAP activity.
Bars: 400 m (upper panels), 100 m (lower panel) (**, P 
 0.01; ***, P 
 0.001). n  4 in each group (A to E). Data are representative of 3 independent
experiments (F and G). Numbers next to the gel represent molecular weights (in thousands).
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function (Fig. 7C). The impaired attachment of LysM-TLN1
BMMs does not, however, promote apoptosis (data not shown).
BMMs do not express v3 until they assume the osteoclast
phenotype (32). Talin1, however, also activates other integrins. In
fact, M-CSF promotes talin association with the 1 subunit,
which participates in osteoclast function, as documented by co-
immunoprecipitation and confocal colocalization with exposure
to the cytokine (30, 33) (Fig. 7D and E).
LysM-Cre-mediated TLN1 deletion impairs osteoclast for-
mation. To assess the phenotype of LysM-TLN1 osteoclasts, we
treated Cre and Cre BMMs with M-CSF and RANKL. While
abundant, characteristic osteoclasts emerged in control cultures,
only a few small, adherent, tartrate-resistant acid phosphatase
(TRAP)-positive, talin1-deficient polykaryons appeared (Fig. 8A
and B). These cells have abnormal cytoskeletons as evidenced by
the presence of numerous minute, actin structures and a paucity
of rings (Fig. 8C). Attesting that these features represent failed
inside-out integrin activation, they are virtually normalized by the
outside-in stimulator, MnCl2 (Fig. 8D). In contrast, expression of
the key osteoclast differentiation markers c-Src and NFATc1 is
unaltered in RANKL-treated LysM-TLN1 cells, regardless of their
capacity to adhere to substrate (Fig. 8E). Similarly, LysM-Cre-
mediated TLN1 deletion does not affect M-CSF-induced total ty-
rosine phosphorylation or signaling important for osteoclast dif-
ferentiation and survival (Fig. 8F). These observations indicate
that osteoclast formation requires matrix adhesion by precursors,
regardless of the expression of proteins that specifically regulate
the cell’s differentiation and function. This conclusion is in keep-
ing with the failure of LysM-TLN1 BMMs to undergo multinucle-
ation when exposed to IL-4 (Fig. 8G).
As the adhesive properties of their precursors are compro-
mised, one would expect mobilization of osteoclasts in response to
a resorptive stimulus to be dampened in LysM-TLN1 mice. To
determine if this is so, we supracalvarially injected Cre and Cre
mice with RANKL or PBS and stained their calvaria for TRAP
activity (34). Whereas control RANKL-injected calvaria contain
numerous TRAP-rich resorption areas, they are much less abun-
dant in those of LysM-TLN1 mice (Fig. 9A and B). Furthermore,
calvarial mRNAs of the osteoclast markers cathepsin K and TRAP
are induced by RANKL in WT but not LysM-TLN1 animals (Fig.
9C). Thus, RANKL-enhanced osteoclast formation, in vitro and in
vivo, requires progenitor cell talin expression.
v3, in the osteoclast, stimulates a cytoskeleton-organizing
complex in which c-Src is a proximal effector (3, 10, 35). To ad-
dress this issue in the context of LysM-TLN1, we generated Cre
and Cre prefusion osteoclasts. They were lifted and either main-
tained in suspension or plated on v3 ligand, which activates
c-Src in control but not talin-deficient cells (Fig. 9D). Tyrosine
phosphorylation of specific components of LysM-TLN1 total cell
lysate is also diminished.
To determine the impact of TLN1 deletion on integrin-di-
rected movement, the lower surfaces of transwell filters were
FIG 7 TLN1 deletion in osteoclast lineage cells disrupts BMM adhesion. (A)
Talin1 protein (left panel) and quantitative PCR (qPCR)-determined talin1
and kindlin3 mRNA (right panel) expression in LysM-TLN1 () and control
() BMMs. (B) CT image and BV/TV of distal femurs of 8-week-old LysM-
TLN1 () and control () mice (**, P 
 0.01). (C) Phase-contrast micros-
copy of LysM-TLN1 () and control () BMMs. Bright cells are those that are
nonadherent. Bar, 100 m. (D) Cytokine-starved WT macrophages were ex-
posed to M-CSF over time. 1 integrin immunoprecipitates were immuno-
blotted for talin and 1 subunit. IgG served as negative control. (E) Serum/
cytokine-starved osteoclasts, differentially immunostained for 1 integrin
subunit (green) and talin (red) were exposed to carrier or M-CSF for 5 min.
Arrows indicate areas of colocalization. Bar, 50m. Data are representative of
at least 3 independent experiments in panels A and C through E, and n 12 in
the experiment illustrated in panel B. Numbers next to the gels represent
molecular weights (in thousands).
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coated with the v3 ligand vitronectin. LysM-TLN1 and control
prefusion osteoclasts were added to transwells in which the lower
chamber did or did not contain M-CSF. Neither genotype mi-
grated toward v3 ligand in the absence of M-CSF (Fig. 9E and
F). In the presence of the activating cytokine, directed migration
of both is increased but that of talin1-deficient cells is less than
one-third of that of WT. Reflective of cytoskeletal dysfunction,
the phagocytic capacity of LysM-TLN1 BMMs is also impaired
(Fig. 9G).
The talin head domain partially rescues talin1-deficient os-
teoclasts. Talin1 consists of a FERM domain-containing head
linked to a long, flexible rod (36). Retroviral expression of the
talin1 head (talin1– 433) in LysM-TLN1 BMMs prompts them to
adhere to plastic and spread (Fig. 10A). Furthermore, the tyrosine
FIG 8 TLN1 deletion in osteoclast lineage cells disrupts osteoclast formation. (A) LysM-TLN1 () and control () BMMs treated with M-CSF and RANKL for
5 days were viewed by phase-contrast microscopy to visualize osteoclasts and nonadherent BMMs. Bar, 100 m. (B) Following removal of nonadherent cells
illustrated in panel A, the cells were stained for TRAP activity. Bar, 400m. (C) Fibrillar actin of bone-residing LysM-TLN1 () and control () osteoclasts was
visualized by rhodamine-phalloidin staining. Bar, 100 m. (D) Bone-residing LysM-TLN1 osteoclasts were exposed to MnCl2 (2 mM) or PBS for 8 h. Fibrillar
actin was visualized by rhodamine-phalloidin staining. Bar, 100 m. (E) BMMs were treated with M-CSF and RANKL (OC) or M-CSF alone (M) for 4 days.
LysM-TLN1 cells were separated into adherent and nonadherent components, whereas all control cells were adherent. c-Src and NFATc1 were immunoblotted.
Actin served as loading control. (F) LysM-TLN1 () and control () BMMs were exposed to M-CSF over time. Lysates were immunoblotted for talin and total
phosphotyrosine content (upper panel) or total and phosphorylated AKT and extracellular signal-regulated kinase (ERK) (lower panel). Actin served as loading
control. (G) LysM-TLN Cre and Cre BMMs were cultured in M-CSF with or without interleukin-4 (IL4) (20 ng/ml) for 24 h. The cells were stained with
hematoxylin. Bar, 100m. Data are representative of at least 5 independent experiments (A to C) or at least 3 independent experiments (D to G). Numbers next
to the gels represent molecular weights (in thousands).
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phosphorylation of adherent, head domain-transduced prefusion
osteoclast lysate is more profound than that of Cre vector con-
trol (Fig. 10B). The talin1 head substantially rescues the appear-
ance and number of LysM-TLN1 TRAP-stained osteoclasts (Fig.
10C) but not their cytoskeletal abnormalities, as manifested by the
persistence of numerous atypical, minute actin structures and a
paucity of rings (Fig. 10D).
Talin1-deficient osteoclasts protect against pathological
bone loss. Reflecting diminished resorption, CT and histomor-
phometric analysis establishes that CtsK-TLN1 mice are substan-
tially protected from bone loss following estrogen deprivation
(Fig. 11A to C). Similarly, the osteoclasts of CtsK-TLN1 mice with
inflammatory arthritis, while abundant, are generally not juxta-
posed to bone and exhibit the crenated appearance of those lack-
ing integrin-activated cytoskeleton-organizing molecules, result-
ing in much less periarticular erosion (Fig. 11D and E). Thus, talin
regulates osteoclast function in physiological and pathological cir-
cumstances.
DISCUSSION
There is compelling evidence that M-CSF and v3 interdepen-
dently remodel the osteoclast cytoskeleton. For example, the cy-
tokine needs v3 to transit the cytoskeleton-organizing GTPase
Rac to its GTP-bound state, and integrin-stimulated Rac, induced
by adherence to bone, requires M-CSF. Hence, v3 and M-CSF
induction of their associated cytoskeleton-organizing signaling
complexes are perhaps related by inside-out activation of the in-
tegrin. In fact, we previously determined that M-CSF activates a
FIG 9 TLN1 deletion in osteoclast lineage cells disrupts osteoclast mobilization. (A) RANKL (50g/mouse/day) was administered supracalvarially to LysM-TLN1 ()
and control () mice for 5 days. Calvaria were fixed and stained for TRAP activity. (B) Calvaria of LysM-TLN1 () and control () mice treated as described for panel
A were subjected to CT. (C) Cathepsin K and TRAP mRNA, isolated from the calvaria shown in panels A and B, was quantitated by qPCR. (D) Cytokine-starved
LysM-TLN1 () and control () prefusion osteoclasts were lifted and maintained in suspension (S) or plated on vitronectin (A) for 30 min. Lysates were immuno-
blotted for total phosphotyrosine (p-Y) and activated c-Src (p-Src). Actin served as loading control. (E) Preosteoclast migration was assessed using transwells in which
the lower membrane surface was coated with vitronectin in the absence or presence of M-CSF as a chemoattractant. The membrane-residing cells were stained with
crystal violet. Bar, 100m. (F) Quantification of cells shown in panel E. (G) Engulfment of apoptotic T cells by LysM-TLN1 () and control () BMMs (*, P
 0.05;
**, P
 0.01). Data are representative of at least 2 independent experiments. Numbers next to the gel represent molecular weights (in thousands).
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hybrid complex of murine v and human 3 (11). We presently
show that the same obtains, to a similar extent, in naïve WT cells.
Having established that M-CSF is capable of activatingv3 in the
bone-resorbing cell, we turned to the causal mechanisms and bi-
ological implications.
Talin recognizes the 3 integrin cytoplasmic domain by first
binding a distal motif containing 3Y747. Alanine knock-in of this
residue largely obviates talin1 recognition and prompts failure of
osteoclast spreading in vitro (17). In contrast to the alanine sub-
stitution, 3Y747F has no effect on osteoclast formation and func-
tion (22). In keeping with this observation, 3Y747F rescues the
3/ osteoclast phenotype as effectively as the WT construct.
Because YF substitution is more conservative than YA, the
disruptive effect of3Y747A on talin1 recognition likely reflects the
conformational change of the integrin rather than failed phos-
phorylation (25).
To more directly determine the role of talin1 in osteoclast for-
mation and function, we targeted the TLN1fl/fl gene by CtsK-Cre,
generating mice with a 5-fold increase in bone mass. In keeping
with integrin dysfunction, CtsK-TLN1 osteoclasts are abundant
but when stressed, such as in the context of inflammatory osteoly-
sis, fail to spread or normally attach to bone.
Because CtsK is expressed late in osteoclastogenesis, Cre re-
combinase driven by the enzyme’s promoter deletes target genes
only in cells substantially committed to the osteoclast phenotype.
To assess the impact of talin deletion throughout the osteoclasto-
genic process, we turned to mice expressing LysM-Cre, which is
active in all myeloid cells. LysM-TLN1 BMMs and prefusion os-
teoclasts fail to attach to substrate, spread, or activate cytoskele-
ton-organizing molecules. LysM-TLN1 prefusion osteoclasts also
do not migrate normally tov3 ligand, another manifestation of
defective integrin and cytoskeletal function. Failure of LysM-
TLN1 cells to spread on substrate or migrate is not due to inade-
quate outside-in integrin activation, since the defect is rescued by
MnCl2. Thus, the functional abnormalities of LysM-TLN1 osteo-
clast lineage cells likely reflect failed inside-out integrin activation.
Despite the robust in vivo skeletal phenotype of CtsK-TLN1
mice, osteoclasts generated in vitro from these animals are normal,
reflecting the persistence of talin protein to the limits of cultured
osteoclast viability. To circumvent this limitation, we attempted
to deleteTLN1fl/fl in vitrowith transduced Cre recombinase. While
we have used this strategy successfully in other circumstances (21,
27), we find it to be gene specific and were unsuccessful in the
context of talin.
Talin contains two principal regions, the head and rod do-
mains, which interact to autoinhibit the protein (13). Rap1 and its
binding partner, RIAM, activate talin1 by exposing its head, which
then associates with cytoplasmic tails of  integrins to disrupt
their inactivating salt bridge and increase ligand affinity. The talin
rod interacts with the cytoskeletal proteins, actin and vinculin.
Given that Rap1 is essential for talin-mediated integrin activation,
in other circumstances, we attempted to delete it in vitro by Cre
transduction and were successful in generating osteoclasts with
disorganized cytoskeletons. With the realization that Rap1 exerts
effects other than talin activation, the identical skeletal appearance
of mice lacking either gene provides compelling evidence that the
normal appearance of osteoclasts derived from CtsK-TLN1
BMMs reflects failed deletion of the target protein.
FIG 10 Talin1 head domain partially rescues LysM-TLN1 osteoclast formation. (A) Talin11– 433 (Head) or vector was retrovirally transduced into LysM-TLN1
BMMs (). Vector was also transduced into control BMMs (). Phase-contrast micrograph of transduced BMMs. Bar, 100 m. (B) Cytokine-starved,
transduced prefusion osteoclasts were maintained in suspension (S) or plated on vitronectin (A) for 30 min. Lysates were immunoblotted for phosphorylated
tyrosine (p-Y). Actin served as loading control. (C) Transduced BMMs cultured in M-CSF and RANKL for 5 days were stained for TRAP activity. Bar, 400 m.
(D) Bone-residing transduced BMMs cultured in M-CSF and RANKL for 5 days were stained with rhodamine-phalloidin to visualize fibrillar actin. Bar, 100m.
Data are representative of at least 3 independent experiments. Numbers next to the gel represent molecular weights (in thousands).
Talin1 and Rap1 Regulate Osteoclasts
February 2013 Volume 33 Number 4 mcb.asm.org 841
 o
n








The magnitude of skeletal resorption is reflective of the num-
ber of osteoclasts and the capacity of the individual cell to degrade
bone. We have shown that the absence of v3 or of members of
its activated cytoskeleton-organizing complex arrests osteoclast
function but not differentiation. In keeping with the essential role
of talin in stimulating this complex, RANKL- and M-CSF-treated
LysM-TLN1 BMMs express normal osteoclastogenic markers and
activate relevant signaling molecules. On the other hand, mirror-
ing the absence of v3 (37), the number of osteoclasts derived
from LysM-TLN1 BMMs in vitro is substantially reduced, a likely
consequence of impaired motility and capacity to multinucleate.
It is also reflected by impairment of LysM-TLN1 mice to mobilize
osteoclasts in response to RANKL in vivo. The fact that two strains
of poorly adherent precursors yield low numbers of osteoclasts in
culture is consistent with the postulate that despite expression of
normal differentiation markers, acquisition of the osteoclast phe-
notype requires matrix adherence and migration and is therefore
impaired in the face of compromised integrin function.
Notwithstanding substantial deficiencies of osteoclast forma-
tion and function in vitro, the basal bone mass of LysM-TLN1
FIG 11 Talin1 deficiency in osteoclasts protects against pathological bone loss.CT image of distal femur (A) and histological images of tibia (C) of CtsK-TLN1
() and control () mice 4 weeks after sham operation or ovariectomy (OVX). Bar, 500 m. (B) CT-determined percentage of bone loss in CtsK-TLN1 ()
and control () mice 4 weeks following ovariectomy, relative to sham operation. (D) TRAP-stained histological sections of ankles of CtsK-TLN1 () and control
() mice 7 days following injection of arthrogenic serum. Bars: 100 m (top panel), 25 m (bottom panel). (E) Percentage of surface (S) exhibiting erosive
features and total number of osteoclasts normalized to bone surface, (the percentage of bone surface to which osteoclasts are juxtaposed) (*, P
 0.05; **, P

0.01). n 7 in each group for panels A to C, and n 4 in panels D and E. Data are representative of at least 2 independent experiments.
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mice, albeit significantly increased, is not as abundant as that of
CtsK-TLN1 animals. This difference, while enigmatic, may repre-
sent relative efficiencies ofTLN1deletion. Temporal differences in
Cre expression may also contribute to this discrepancy, as we have
observed similar inconsistencies in other circumstances involving
the same two Cre-expressing mice (8). Regardless of this conun-
drum, LysM-TLN1 mice provided us the means of assessing the
role of talin’s integrin-activating domain in osteoclasts. We find
that expression of the talin1 head in LysM-TLN1 BMMs normal-
izes their capacity to adhere to matrix and spread. The transduced
head also substantially increases the number of osteoclasts re-
cruited by M-CSF and RANKL. However, consistent with the es-
sential role of the talin1 rod in binding to cytoskeletal proteins
(25), neither osteoclast abundance nor appearance is completely
rescued in LysM-TLN1 cells expressing the talin head alone. Thus,
intact talin is required to functionally link the integrin to the os-
teoclast cytoskeleton.
The pragmatic aspect of our study relates to the fact that v3
is the only integrin that has served as a clinically tested therapeutic
target in the context of osteoporosis (38). The bone-sparing effects
of a small-molecule v3 inhibitor are relatively modest and thus
have not been further pursued. Because the osteopetrotic pheno-
types of CtsK-TLN1, CtsK-Rap1, and kindlin3/ mice are more
profound than of those of mice lacking the 3 integrin (23) or
3Y747A, the therapeutic failure of v3 inhibition likely reflects
compensation by other integrins, such as those of the 1 family.
Hence, targeting common motifs of numerous integrins that rec-
ognize essential activating molecules, such as talin, Rap1, or kind-
lin3, should be a more promising strategy for preventing and
treating pathological osteolysis. Furthermore, our data establish
that therapeutic targeting needs not be extant throughout osteo-
clastogenesis, which would impact other myeloid cells such as
inflammatory macrophages. The fact that inhibition of integrin
function late in the course of osteoclast development yields
healthy mice substantially resistant to inflammatory osteolysis
and estrogen-deficient osteoporosis buttresses this argument.
Thus, we propose the following model of M-CSF-mediated
organization of the osteoclast cytoskeleton (Fig. 12). Occupancy
of c-Fms changes Rap1-GDP to its active, GTP-bound form.
Rap1-GTP induces talin to associate with a variety of  subunit
cytoplasmic domains, thus transiting the integrins to their active,
high-affinity conformation. Upon binding bone matrix-residing
ligand, the integrin activates a canonical signaling complex, the
most distal established member being Rac, thus organizing the
osteoclast’s cytoskeleton and enabling the cell to resorb bone.
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